Crossmark

Validation of a predictive risk score of aggressive PK/PD target non-attainment with continuous infusion piperacillin/tazobactam or meropenem in critically ill patients having documented Gram-negative infections

Crossref DOI link: https://doi.org/10.1186/s44158-025-00324-0

Published Online: 2025-12-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gatti, Milo

Grimaldi, Pierantonio

Rinaldi, Matteo

Siniscalchi, Antonio

Tonetti, Tommaso

Viale, Pierluigi

Pea, Federico
License Information

Text and Data Mining valid from 2025-12-04

Version of Record valid from 2026-01-12
More Information

Article History

Received: 21 October 2025

Accepted: 26 November 2025

First Online: 4 December 2025

Declarations

:

: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the local ethical committee (No. 308/2021/Oss/AOUBo on 17 May 2021, No. EM232–2022_308/2021/Oss/AOUBo on 16 March 2022, EM449-2023_308/2021/Oss/AOUBo on 17 April 2024). Informed written consent was waived due to the retrospective and observational nature of the study.

: All authors approved the final version submitted for publication.

: M.G. received personal fees from Angelini, AdvanzPharma, and Viatris; P.V. has served as a consultant for Biomerieux, Gilead, Merck Sharp & Dohme, Nabriva, Nordic Pharma, Pfizer, Thermo-Fisher and Venatorx, and received payment for serving on the speaker’s bureau for Correvio, Gilead, MerckSharp & Dohme, Nordic Pharma, and Pfizer; F.P. participated in speaker bureau for Angelini, BeiGene, Gilead, InfectoPharm, Menarini, Merck Sharp & Dohme, Pfizer, and Shionogi, and in advisory boards for BeiGene, Merck Sharp & Dohme, Pfizer, and Viatris. The authors report no other conflicts of interest in this work.

Document is current

Any future updates will be listed below